The SOL Study
SOL is a clinical trial to determine if an investigational drug, OTX-TKI, is safe and effective for treating wet AMD1
About OTX-TKI
OTX-TKI is a small implant (loaded with the study drug, axitinib) that is broken down and absorbed by the body over time. Once injected into the eye cavity, it will slowly dissolve and deliver the drug to the eye.2,3
The implant is designed to deliver the drug consistently to the eye for months.2,3
You may qualify for the SOL study if you1:
01
Have wet AMD in at
least 1 eye
02
Have not previously been
treated for wet AMD in the
affected eye
03
Are older than 50 years of
age at the start of study
treatment
Visit clinicaltrials.gov for more information about the SOL study, including contact information for those conducting the study and the study locations. You can also learn more about the sponsor of the study, Ocular Therapeutix.
Find a Site
To find out if you are eligible to take part in the SOL study, start with a screening at a clinical trial site near you.
REFERENCES: 1. Study to evaluate the efficacy and safety of intravitreal OTX-TKI (Ocular Therapeutix) (axitinib implant) in subjects with neovascular age-related macular degeneration. NCT06223958. Updated July 5, 2024. Accessed July 15, 2024. https://clinicaltrials.gov/study/NCT06223958. 2. Tan CS, et al. Clin Ophthalmol. 2022;16:917-933.
3. Boyer DS, et al. Evaluating safety, tolerability and biological activity of OTX-TKI, a hydrogel-based, sustained-release intravitreal axitinib implant, in subjects with neovascular age-related macular degeneration. Presented at the AAO Annual Meeting; November 13-15, 2020; Virtual. https://ocutx.gcs-web.com/static-files/c03d01fe-165c-4dc0-bd1f-2c81ebb06cb2.